Literature DB >> 24284427

Antiviral Sulfoquinovosyldiacylglycerols (SQDGs) from the Brazilian brown seaweed Sargassum vulgare.

Erwan Plouguerné1, Lauro M de Souza, Guilherme L Sassaki, Jéssica Figueiredo Cavalcanti, Maria Teresa Villela Romanos, Bernardo A P da Gama, Renato Crespo Pereira, Eliana Barreto-Bergter.   

Abstract

Total lipids from the Brazilian brown seaweed Sargassum vulgare were extracted with chloroform/methanol 2:1 and 1:2 (v/v) at room temperature. After performing Folch partition of the crude lipid extract, the lipids recovered from the Folch lower layer were fractionated on a silica gel column eluted with chloroform, acetone and methanol. The fraction eluted with methanol, presented a strong orcinol-positive band characteristic of the presence of sulfatides when examined by TLC. This fraction was then purified by two successive silica gel column chromatography giving rise to fractions F4I86 and F4II90 that exhibited strong activity against herpes simplex virus type 1 and 2. The chemical structures present in both fractions were elucidated by ESI-MS and ¹H/¹³C NMR analysis HSQC fingerprints based on their tandem-MS behavior as Sulfoquinovosyldiacylglycerols (SQDGs). The main SQDG present in both fractions and responsible for the anti-herpes activity observed was identified as 1,2-di-O-palmitoyl-3-O-(6-sulfo-α-D-quinovopyranosyl)-glycerol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284427      PMCID: PMC3853750          DOI: 10.3390/md11114628

Source DB:  PubMed          Journal:  Mar Drugs        ISSN: 1660-3397            Impact factor:   5.118


1. Introduction

Herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) are the most widely studied human herpes viruses [1] with an estimated 60%–95% of the adult population infected by at least one of them [1,2]. HSV-1 is generally related to oral–facial infections and encephalitis, whereas HSV-2 is responsible for genital infections, and can be transferred from infected mothers to neonates [1]. Moreover, HSV infections are recognized as a risk factor for human immunodeficiency virus (HIV) infection [3]. Efficient anti-herpes drugs already exist, but their extensive use can generate side effects and may also lead to the rise of drug-resistant virus strains [4,5]. Consequently, new types of anti-herpes compounds are urgently needed. Marine organisms are a huge source of natural products with biological activities. Products of primary metabolism like amino acids, carbohydrates and proteins, are vital for maintaining life processes, while others such as alkaloids, phenolics, steroids, terpenoids, are secondary metabolites that have ecological, toxicological and pharmacological significance [6,7], encompassing bioactivities such as antiparasitic, antitumor, antimicrobial and antifoulant effects [8]. Recently, a great deal of interest has been expressed regarding compounds from seaweeds as potential antiviral agents [9]. Polysaccharides (sulfated polysaccharides in particular), poliketides, terpenoids or peptides with anti-HSV activities have been isolated from these marine organisms [10,11,12,13]. Glycolipids represent a less studied class of antiviral secondary metabolites [14]. Seaweeds synthesize three major types of glycolipids: monogalactosyldiacylglycerides (MGDG), digalactosyldiacylglycerides (DGDG), and sulfoquinovosyldiacylglycerides (SQDG) [15]. SQDG has an important biological function in photosynthetic plant tissues [16], exhibits high biological activity [17], affects HIV [18] and neoplastic and inflammatory processes [17,19]. In a recent study, de Souza and coworkers [14] isolated SQDG from the red seaweed Osmundaria obtusiloba that exhibited potent anti-HSV-1 and HSV-2 activities. A SQDG with anti-HSV-1 activity was isolated from the microalga Spirula platensis [20]. Wang and coworkers [21] highlighted the anti-HSV-2 activity of a SQDG isolated from the green seaweed Caulerpa racemosa. As SQDG is the main glycolipid found in brown seaweeds of the order Fucales [22], we have chosen the brown seaweed Sargassum vulgare as a model in order to isolate and test its glycolipids as potencial anti-HSV-1 and HSV-2 agents.

2. Results and Discussion

2.1. Lipid Fractionation

Total lipids from the brown seaweed Sargassum vulgare were successively extracted with chloroform/methanol 2:1 and 1:2 (v/v) at room temperature according to previous studies [14,23]. After filtration, the extracts were combined, concentrated in vacuo and the crude lipid extract was partitioned according to Folch and coworkers [24]. The lower layer was evaporated and fractionated on silica gel column chromatography using chloroform, acetone, and methanol as solvents (Figure 1). Fractions were analyzed by TLC, developed with CHCl3:CH3OH:2M NH4OH (40:10:1 v/v/v) and the spots visualized with iodine and by spraying with orcinol/H2SO4 [23]. The resulting fractions were combined in four fractions, F1, F2, F3 and F4 according to their TLC profiles. Thin-layer chromatography of F4 revealed an orcinol-positive band with chromatographic mobility corresponding to a sulfatide. This fraction was then chosen to carry out the purification protocol.
Figure 1

Purification protocol of sulfoquinovosyldiacylglycerols from Sargassum vulgare.

Purification protocol of sulfoquinovosyldiacylglycerols from Sargassum vulgare. The F4 fraction was first treated with activated charcoal in order to remove the pigments, and was then purified on a silica gel column, which was sequentially eluted with chloroform/methanol with increasing concentrations of methanol (95:5, 90:10, 80:20, 50:50, v/v) and finally with 100% methanol, providing ninety-five sub-fractions. These fractions were pooled according to their TLC profiles, resulting in twelve final fractions: F4I1, F4I5, F4I7, F4I11, F4I23, F4I35, F4I41, F4I63, F4I69, F4I86, F4I90 and F4I95. Fraction F4I90 was further purified on a silica gel column, which was sequentially eluted with chloroform/methanol with increasing concentrations of methanol (90:10, 80:20 v/v) and finally with 100% methanol, providing hundred fifty-one sub-fractions. These fractions were pooled according to their TLC profiles, resulting in seven final fractions: F4II1, F4II13, F4II63, F4II70, F4II90, F4II121, and F4II148. Fractions F4I86 and F4II90, which TLC profiles indicate the presence of SQDGs, were then analyzed using ESI-MS and NMR, and their antiviral activity was tested against HSV-1 and HSV-2.

2.2. Mass Spectrometry of Sulfolipids

The spectrum obtained in negative MS1 from fraction F4I86 exhibited six deprotonated ions with m/z 766, 794, 808, 820, 836 and 892 [M − H]− compatible with sulfoquinovosyldiacylglycerol structures. In order to confirm the structures, the ions at m/z 766, 794, 808, 820, 836 and 892 were fragmented by the second stage tandem-MS. Each ion gave fragments at m/z 225, 165, 153, 95 and 81 characteristic of the 6-deoxy-6-sulfono-hexosyl residue of the SQDG (Figure 2).
Figure 2

Spectrum from MS1 obtained in negative ionization mode from Fraction F4I86. The fragmentation pathway of the ion at m/z = 794 is compatible with the structure of 1,2-di-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol.

Spectrum from MS1 obtained in negative ionization mode from Fraction F4I86. The fragmentation pathway of the ion at m/z = 794 is compatible with the structure of 1,2-di-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol. The ion at m/z 793.9 was the most abundant and gave fragments at m/z 537.5 (M − C16:0 from the sn-2 position), 536.9 (M–C16:0 from the sn-1 position), 224.7, 164.8, 152.8, 95.2 and 81.1, as indicated in the fragmentation pathway, consistent with a SQDG structure, esterified by two palmitic acids (C16:0) (Figure 2). The structure was confirmed comparing our data to the fragmentation pathway already described by Zianni and coworkers [25] for a similar SQDG isolated in a lipid extract from spinach leaves. The fragmentation pathway of the six deprotonated ions with m/z at 765.7, 793.6, 807.4, 819.5, 835.9 and 891.9 [M − H]−, is compatible with sulfoquinovosyldiacylglycerol structures represented in Table 1 and Figure 3.
Table 1

Identification of sulfoquinovosyldiacylglycerides (SQDGs) present in fractions F4I86 and F4II90.

FractionCompoundR1/R2[M − H] m/z[M − R1] m/z[M − R2] m/z
F4I86, F4II90S1C14:0/C16:0765.7536.7508.6
F4I86, F4II90S2C16:0/C16:0793.6537537
F4I86, F4II90S3C17:0/C16:0807.4537.4551.2
F4I86S4C18:1/C16:0819.5537.1563
F4I86, F4II90S5C19:0/C16:0835.9537.6579
F4I86S6C23:0/C17:0891.9536.8635.6
Figure 3

Characteristic tandem-MS (MS1) profiles obtained from SQDGs isolated from fractions F4I86 and F4II90. The fragmentation indicated differences in the fatty acid chain lengths and the putative structures were depicted for each SQDG species. (S1) 1-O-myristoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S2) 1,2-di-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S3) 1-O-margaroyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S4) 1-O-oleoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S5) 1-O-nonadecanoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S6) 1-O-tricosanoyl-2-O-margaroyl-3-O-(6-sulfoquinovopyranosyl)-glycerol.

Identification of sulfoquinovosyldiacylglycerides (SQDGs) present in fractions F4I86 and F4II90. Characteristic tandem-MS (MS1) profiles obtained from SQDGs isolated from fractions F4I86 and F4II90. The fragmentation indicated differences in the fatty acid chain lengths and the putative structures were depicted for each SQDG species. (S1) 1-O-myristoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S2) 1,2-di-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S3) 1-O-margaroyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S4) 1-O-oleoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S5) 1-O-nonadecanoyl-2-O-palmitoyl-3-O-(6-sulfoquinovopyranosyl)-glycerol, (S6) 1-O-tricosanoyl-2-O-margaroyl-3-O-(6-sulfoquinovopyranosyl)-glycerol. The spectrum obtained from fraction F4II90 presents the same ions that fraction F4I86, with the exception of the ions at m/z = 819.5 and m/z = 891.9 that correspond to SQDG structures esterified by palmitic and oleic acids, and by palmitic and tricosanoic acids respectively.

2.3. NMR Spectroscopy of Sulfolipids

The structure of the main sulfoglycolipid present in fraction F4I86 and F4II90 was confirmed by 1H and 13C NMR analysis, based on HSQC fingerprints. The anomeric region (H1/C1 Qui) contained a single signal at δ 4.78/99.3, consistent with α-quinovopyranosyl group. Moreover, 1H/13C-HSBC signals at δ 3.25, 2.990/53.5 were observed (Figure 4). The presence of doublets of CH2 signals in a high-field region is characteristic of S-substituted C-6, typical of 6-sulfo-α-quinovopyranosyl unit [14,26,27].
Figure 4

Partial fingerprint spectrum 2D-1H/13C-HSQC analysis of the polar head group of sulfoquinovosyldiacylglycerol. Gly = glycerol; Qui = quinovose.

Partial fingerprint spectrum 2D-1H/13C-HSQC analysis of the polar head group of sulfoquinovosyldiacylglycerol. Gly = glycerol; Qui = quinovose. These results and those obtained from mass spectrometry allowed us to identify the main SQDG from fractions F4I86 and F4II90 as 1,2-di-O-palmitoyl-3-O-(6-sulfo-α-d-quinovopyranosyl)-glycerol.

2.4. Antiviral Activity

Both fractions F4I86 and F4II90 demonstrated strong antiviral activity against HSV-1 and HSV-2 (Table 2). The percentage of inhibition of fraction F4I86 was 99.9 against HSV-1 and HSV-2. The fraction F4II90 inhibited HSV-1 and HSV-2 with a percentage of 96 and 99.9, respectively.
Table 2

Anti HSV-1 and HSV-2 of fractions F4I86 and F4II90 isolated from S. vulgare.

CompoundsCC50 (μg/mL)MNTC (μg/mL)Inhibition %
HSV-1HSV-2
S. vulgare F4I86>2005099.999.9
S. vulgare F4II90>2005096.099.9
Acyclovir>20020099.099.9

CC50, 50% Cytotoxic Concentration; MNTC, Maximum Non-Toxic Concentration; HSV-1, Herpes Simplex Virus 1; HSV-2, Herpes Simplex Virus 2; Acyclovir, standard compound.

Anti HSV-1 and HSV-2 of fractions F4I86 and F4II90 isolated from S. vulgare. CC50, 50% Cytotoxic Concentration; MNTC, Maximum Non-Toxic Concentration; HSV-1, Herpes Simplex Virus 1; HSV-2, Herpes Simplex Virus 2; Acyclovir, standard compound. Our results are compatible with previous data obtained by de Souza and coworkers [14] who isolated SQDGs with anti-HSV activity from the Brazilian red seaweed Osmundaria obtusiloba. Wang and coworkers [21] isolated and purified a SQDG from the n-butanol fraction of Caulerpa racemosa with anti-HSV2 activity. SQDG with anti-HSV1 activity was isolated from the microalga Spirulina platensis [20]. Biological activity from SQDGs may be related to the fatty acids that esterify the sulfoquinosyl moiety [28]. The principal ion present in fractions F4I86 and F4II90 corresponds to the structure of a SQDG esterified by two palmitic acids (C16:0). Such observation is consistent with previous studies that already identified palmitic acid as the most abundant fatty acid present in marine sulfonoglycolipids [18,22,28,29,30,31,32,33,34]. Indeed, palmitic acid is present in all the SQDGs identified in fraction F4II90, and is part of the structure of five of the six SQDGs identified in fraction F4I86. Palmitic acid as a free fatty acid has been characterized as an antitumor compound present in the red seaweed Amphiroa zonata [35], as well as being an antibacterial agent [36]. Santoyo and coworkers [37] suggested that palmitic acid present in extracts from the microalgae Dunaliella salina and Haematococcus pluvialis may also be involved in the anti-HSV-1 activity. Recently, Lee and coworkers [38] demonstrated that palmitic acid purified from Sargassum fusiforme extract binds to the CD4 cell receptor, blocking HIV-1 entry and infection. Another possible explanation for the antiviral activity of SQDGs is based on the presence of the sulfonate group. As reported by Spear [39], the envelope of HSV contains five glycoproteins (gB, gC, gD, gH and gL) that participate in viral entry by binding to specific receptors present on the cell surface. Within these receptors, heparan sulfate can bind to gB or gC, facilitating the binding of viral glycoproteins to other host cell receptors and allowing the fusion of viral envelop with cell membrane. Such interaction between heparan sulfate and viral glycoproteins may be perturbed by the presence of SQDGs. Indeed, the negatively charged sulfonate group of the SQDGs may interact with positively charged protein sites, therefore explaining the antiviral activity exhibited by these sulfolipids. The relation between the degree of sulfonation and antiviral activity has been highlighted in marine polysaccharides [40]. However, the strong HSV antiviral activity that characterizes marine sulfated polysaccharides, particularly marine heparinoid polysaccharides, is also related to the close structural analogy between these compounds and the heparin sulfate cell receptor [41]. In the case of SQDGs no such analogy exists, and future studies will be necessary to investigate how sulfolipids may interfere in the binding between viral glycoprotein and heparin sulfate cell receptors.

3. Experimental Section

3.1. Biological Material

Thalli of S. vulgare were collected by free diving in the shallow subtidal zone from Ilha de Itacuruçá, a large nearshore island inside Sepetiba Bay (Mangaratiba district, Rio de Janeiro State, Southeastern Brazil—22°56′ S, 43°52′ W). After collection, specimens of S. vulgare were immediately transferred to the laboratory in isothermic boxes filled with local seawater, where they were gently washed in seawater, sorted, and carefully cleaned from associated biota. Thalli were then freeze-dried and ground to a fine powder before performing extraction.

3.2. Extraction and Fractionation of Lipids

The powder obtained from S. vulgare freeze-dried specimens was successively extracted at room temperature with chloroform/methanol 2:1 and 1:2 (v/v). After filtration, the extracts were combined, dried and the crude lipid extract was partitioned according to Folch and coworkers [24]. The lipids recovered from the Folch lower phase were fractionated on a silica gel column, which was eluted with chloroform, acetone and methanol, giving rise to fractions F1–F4. Fraction F4, eluted with methanol and enriched in sulfatides was further purified on a silica gel column, which was sequentially eluted with chloroform/methanol with increasing concentrations of methanol (95:5, 90:10, 80:20, 50:50 v/v) and finally 100% methanol. The resulting fractions were combined in twelve final fractions. Fraction F4I86 was guarded for further analyses and fraction F4I90, eluted with 80/20 chloroform/methanol, was further purified on a second silica gel column yielding a purified sulfolipid fraction, F4II90. All the fractions were analyzed by TLC developed with CHCl3:CH3OH: 2 M NH4OH (40:10:1 v/v) and the spots visualized with iodine and by spraying with orcinol/H2SO4 [42].

3.3. Mass Spectrometry

The samples were prepared in MeOH at 1 mg/mL, then diluted to 0.1 mg/mL in MeOH-H2O (7:3, v/v) and direct infused into ESI source, at a flow rate of 10 μL/min, following the protocol described by de Souza and coworkers [14]. The MS analysis was carried out in an electrospray ionization mass spectrometry (ESI-MS), model Quattro-LC (Waters) with a triple-quadrupole mass analyzer, operating at atmospheric pressure ionization (API), assisted by a syringe pump (Model KDS-100-CE, KD Scientific, Holliston, MA, USA) for sample infusion. Nitrogen was used as nebulizing and desolvation gas and the ionization energies were 50 V on the cone and 2 kV on the capillary, operating in the negative ionization mode. The second stage tandem-MS was obtained by collision induced dissociation mass spectrometry (CID-MS) using argon as collision gas and collision energies ranging between 35 and 60 eV.

3.4. Nuclear Magnetic Resonance

NMR analyses were performed on a Bruker Avance III 400 MHZ spectrometer with a 5 mm inversed gradient probe. The samples were dissolved in deuterated chloroform and methanol (1:1, v/v) at 20 mg/mL. Two-dimensional homo- and heteronuclear 1H/13C correlation experiments (HSQC) were developed. The chemical shifts (δ = ppm) were obtained on the basis of tetramethylsilane shifts (δ13C = 0; δ1H = 0) [14].

3.5. Cells and Viruses

Vero cells (African green monkey kidney) were grown in Eagle’s minimum essential medium (Eagle-MEM) and supplemented with 10% (v/v) fetal bovine serum, glutamine (2 mM), garamycin (50 μg/mL), fungizone (amphotericin B) (2.5 μg/mL), NaHCO3 (0.25%) and HEPES (10 mM). HSV-1 and HSV-2 were isolated from a typical lip and genital lesion respectively, in the Virology Department of the Federal University of Rio de Janeiro (UFRJ), Brazil. Viruses were typed by polymerase chain reaction (PCR) using specific primers for identification [14,43].

3.6. Cytotoxicity Assay

The cytotoxicity of glycolipids was performed by incubating triplicate Vero cell (African green monkey kidney cell) line monolayers cultivated in 96-well microplates with two-fold serial dilutions (200–3.1 μg/mL) of the SQDG fractions for 48 h at 37 °C in a 5% CO2 atmosphere. Cellular viability was evaluated by the neutral red dye-uptake method [44]. The 50% cytotoxic concentration (CC50) was defined as the SQDG concentration, which caused a 50% reduction in the number of viable cells.

3.7. Antiviral Activity Assay

The antiviral activity of SQDG and acyclovir was evaluated by the titer reduction. The virus titers were calculated using the Reed and Muench statistical method [45] and expressed as 50% tissue culture infective dose (TCID50) per mL. Vero cell monolayers were treated with the SQDG and acyclovir at the MNTC and 100 TCID50/mL of HSV-1 or HSV-2 suspensions were added to treated and untreated cell cultures and incubated at 37 °C for 48 h in a 5% CO2 atmosphere. After incubation, the supernatant was collected and virus titers in treated and untreated cells were determined. The antiviral activity was expressed as percentage of inhibition (PI) [46] using antilogarithmic TCID50 values as follows: PI = [1 − (antilogarithmic test value/antilogarithmic control value)] × 100.

4. Conclusions

Antiviral SQDGs were isolated and characterized for the first time in Sargassum vulgare from Brazil. Other studies already highlighted antifouling, anticoagulant, antithrombotic, antioxidant and anti-inflammatory activities from S. vulgare extracts and isolated compounds. Our results reinforce the potential of S. vulgare as a source of natural products with biotechnological applications. Future studies will be necessary to understand more precisely the mechanism of action of SQDGs and to fully determine the potential applications of these seaweed compounds.
  30 in total

1.  Sulfonoglycolipids from the lichenized basidiomycete Dictyonema glabratum: isolation, NMR, and ESI-MS approaches.

Authors:  G L Sassaki; P A Gorin; C A Tischer; M Iacomini
Journal:  Glycobiology       Date:  2001-04       Impact factor: 4.313

Review 2.  Marine natural products.

Authors:  John W Blunt; Brent R Copp; Robert A Keyzers; Murray H G Munro; Michèle R Prinsep
Journal:  Nat Prod Rep       Date:  2011-12-22       Impact factor: 13.423

3.  Glycolipids from the red alga Chondria armata (Kutz.) Okamura.

Authors:  Ammar Al-Fadhli; Solimabi Wahidulla; Lisette D'Souza
Journal:  Glycobiology       Date:  2006-06-24       Impact factor: 4.313

4.  Structure and antiviral activity of sulfated fucans from Stoechospermum marginatum.

Authors:  Utpal Adhikari; Cecilia G Mateu; Kausik Chattopadhyay; Carlos A Pujol; Elsa B Damonte; Bimalendu Ray
Journal:  Phytochemistry       Date:  2006-11       Impact factor: 4.072

5.  Structural features and in vitro antiviral activities of sulfated polysaccharides from Sphacelaria indica.

Authors:  Shruti S Bandyopadhyay; Mojdeh Heidary Navid; Tuhin Ghosh; Paul Schnitzler; Bimalendu Ray
Journal:  Phytochemistry       Date:  2010-12-15       Impact factor: 4.072

6.  AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae).

Authors:  K R Gustafson; J H Cardellina; R W Fuller; O S Weislow; R F Kiser; K M Snader; G M Patterson; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1989-08-16       Impact factor: 13.506

7.  Antiherpetic activity of a sulfated polysaccharide from Agaricus brasiliensis mycelia.

Authors:  Francielle Tramontini Gomes de Sousa Cardozo; Carla Maísa Camelini; Alessandra Mascarello; Márcio José Rossi; Ricardo José Nunes; Célia Regina Monte Barardi; Margarida Matos de Mendonça; Cláudia Maria Oliveira Simões
Journal:  Antiviral Res       Date:  2011-07-20       Impact factor: 5.970

Review 8.  Treatment of herpes simplex virus infections.

Authors:  Rebecca C Brady; David I Bernstein
Journal:  Antiviral Res       Date:  2004-02       Impact factor: 5.970

9.  Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga.

Authors:  Hideki Harada; Uki Yamashita; Hideyuki Kurihara; Eri Fukushi; Jun Kawabata; Yuto Kamei
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

Review 10.  The antiviral activities and mechanisms of marine polysaccharides: an overview.

Authors:  Wei Wang; Shi-Xin Wang; Hua-Shi Guan
Journal:  Mar Drugs       Date:  2012-12-12       Impact factor: 5.118

View more
  13 in total

Review 1.  Antimicrobial Lipids from Plants and Marine Organisms: An Overview of the Current State-of-the-Art and Future Prospects.

Authors:  Eliana Alves; Marina Dias; Diana Lopes; Adelaide Almeida; Maria do Rosário Domingues; Felisa Rey
Journal:  Antibiotics (Basel)       Date:  2020-07-24

Review 2.  Antifungal and antiviral products of marine organisms.

Authors:  Randy Chi Fai Cheung; Jack Ho Wong; Wen Liang Pan; Yau Sang Chan; Cui Ming Yin; Xiu Li Dan; He Xiang Wang; Evandro Fei Fang; Sze Kwan Lam; Patrick Hung Kui Ngai; Li Xin Xia; Fang Liu; Xiu Yun Ye; Guo Qing Zhang; Qing Hong Liu; Ou Sha; Peng Lin; Chan Ki; Adnan A Bekhit; Alaa El-Din Bekhit; David Chi Cheong Wan; Xiu Juan Ye; Jiang Xia; Tzi Bun Ng
Journal:  Appl Microbiol Biotechnol       Date:  2014-02-23       Impact factor: 4.813

3.  Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis.

Authors:  Daman Reynolds; Michael Huesemann; Scott Edmundson; Amy Sims; Brett Hurst; Sherry Cady; Nathan Beirne; Jacob Freeman; Adam Berger; Song Gao
Journal:  Algal Res       Date:  2021-05-18       Impact factor: 4.401

Review 4.  Glycolipids from seaweeds and their potential biotechnological applications.

Authors:  Erwan Plouguerné; Bernardo A P da Gama; Renato C Pereira; Eliana Barreto-Bergter
Journal:  Front Cell Infect Microbiol       Date:  2014-12-17       Impact factor: 5.293

5.  Valorization of Lipids from Gracilaria sp. through Lipidomics and Decoding of Antiproliferative and Anti-Inflammatory Activity.

Authors:  Elisabete da Costa; Tânia Melo; Ana S P Moreira; Carina Bernardo; Luisa Helguero; Isabel Ferreira; Maria Teresa Cruz; Andreia M Rego; Pedro Domingues; Ricardo Calado; Maria H Abreu; Maria Rosário Domingues
Journal:  Mar Drugs       Date:  2017-03-02       Impact factor: 5.118

Review 6.  Marine Pharmacology in 2012-2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Orazio Taglialatela-Scafati; Nobuhiro Fusetani
Journal:  Mar Drugs       Date:  2017-08-29       Impact factor: 5.118

Review 7.  Total synthesis and structure-activity relationship of glycoglycerolipids from marine organisms.

Authors:  Jun Zhang; Chunxia Li; Guangli Yu; Huashi Guan
Journal:  Mar Drugs       Date:  2014-06-18       Impact factor: 5.118

8.  Lipids and fatty acids of nudibranch mollusks: potential sources of bioactive compounds.

Authors:  Natalia V Zhukova
Journal:  Mar Drugs       Date:  2014-08-19       Impact factor: 5.118

Review 9.  Bioprospecting of Marine Macrophytes Using MS-Based Lipidomics as a New Approach.

Authors:  Elisabete Maciel; Miguel Costa Leal; Ana Isabel Lillebø; Pedro Domingues; Maria Rosário Domingues; Ricardo Calado
Journal:  Mar Drugs       Date:  2016-03-08       Impact factor: 5.118

Review 10.  Lipidomic Approaches towards Deciphering Glycolipids from Microalgae as a Reservoir of Bioactive Lipids.

Authors:  Elisabete da Costa; Joana Silva; Sofia Hoffman Mendonça; Maria Helena Abreu; Maria Rosário Domingues
Journal:  Mar Drugs       Date:  2016-05-19       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.